|
Article Start
Solae, a leader in soy
protein innovation and technology, unveiled a new study today at the
8th International Symposium on the Role of Soy in Health Promotion
and Chronic Disease Prevention and Treatment. A new meta-analysis
confirms that soy protein consumption can lead to a meaningful and
significant reduction in blood cholesterol levels. Solae is also
presenting a poster that defines one of the possible mechanisms by
which soy lowers cholesterol and protects against heart disease.
Numerous studies show that soy consumption may be associated with a
lower incidence of certain chronic diseases, notably heart disease.
These findings led to the approval of the health claim for soy protein
in the prevention of heart disease risk by the Food %26 Drug
Administration (FDA) in 1999. The FDA-approved health claim helps
promote the daily consumption of 25 grams of soy for lowering
cholesterol levels and reducing the risk of heart disease.
It has been nearly a decade since the health claim was awarded and
numerous studies have been published since then. Solae's research
team conducted a meta-analysis to evaluate the totality of the
evidence, that is, studies from before and after the original health
claim to determine the net effect of soy on blood cholesterol
reduction. Solae's research team reviewed and ranked more than 150
studies using the FDA's 2007 evidence-based review guidance for
scientific evaluation of health claims. Forty-six of the studies
that were deemed high or moderate quality were included in the final
meta-analysis.
The meta-analysis found reductions in total cholesterol of 9.54 mg/dL
and reductions in LDL cholesterol of 7.12 mg/dL (which is about a 4
and 5 percent reduction respectively). The meta-analyses also looked
at individuals who had high and normal blood cholesterols and found
that soy protein consumption resulted in a significant reduction in
blood cholesterol for both groups.
"These findings build on the body of evidence that continues to
support currently approved health claims for the role of soy protein
in lowering heart disease risk," said Priscilla Samuel, Ph.D., lead
researcher of the meta-analysis and director of Nutrition at Solae.
"Coronary heart disease is still the leading cause of death globally.
Our research confirms that consuming soy protein is one way to reduce
total cholesterol."
In addition to the meta-analysis, the conference also includes a
poster presentation that highlights a possible mechanism by which soy
protein reduces cholesterol and thereby protects against heart
disease. This new study suggests that soy protein binds bile acids in
the digestive tract leading to excretion of these bile acids from the
body. This bile acid excretion results in the liver extracting
cholesterol for bile acid synthesis, which in turn results in an
overall decrease in blood cholesterol levels.
These studies further confirm the heart health benefits of soy
protein. Research continues to show that consuming 25 grams of soy
protein per day results in significant and meaningful reductions in
total cholesterol and LDL cholesterol. Soy protein can easily be a
part of a healthy, low-cholesterol, low-fat diet and can be
incorporated into a variety of food forms, including bars, beverages
and cereal, to make eating heart healthy convenient for consumers.
Solae is the world leader in developing innovative soy-based
technology and ingredients for the food, meat and nutritional
products industries. Solae provides solutions that deliver a unique
combination of functional, nutritional and economic benefits to our
customers. At Solae, the journey to innovation begins with nature.
Solae takes one of nature's best resources, the soybean, and create
nutritious and great-tasting ingredients. Solae's mission is to
provide solutions for today while innovating for tomorrow. With more
than 1,000 products used by more than 3,500 customers, Solae's soy
ingredients are enjoyed by consumers around the world in products
such as baked goods, beverages, nutrition bars, meats, vegetarian
meals and much more. Headquartered in St. Louis, Missouri, USA, with
annual revenue exceeding $1 billion, the company was formed through a
joint venture between Bunge Limited (NYSE: BG) and DuPont (NYSE: DD).
http://www.solae.com
Article End
|
